Fight against biolab was lost, but with an affordable-housing victory
The executive committee of the Cambridge Residents Alliance writes to thank the residents who participated in efforts to limit the size of the proposed Forest City biolab building.
Forest City is looking for affordable-housing site, exec promises in bid for Central Square zoning
The search is under way for a site to hold 25 units of affordable housing in trade for the ability to build near Central Square, said Peter Calkins, executive vice president and chief operating officer for the developer Forest City.
Forest City tweaks Central Square plans to add appeal, but tweaks become targets
Developer Forest City’s plan for a giant lab and office building was back Thursday with some people-pleasing tweaks, including a promise to build 25 units of affordable housing and commitment to locally owned, affordable retail. But the changes weren’t pleasing enough for councillors or residents.
Changes in Kendall make cafeteria rule for Biogen Idec unnecessary, officials argue
The pretense that Biogen Idec’s return to Cambridge was threatened by a cafeteria zoning requirement was abandoned Wednesday, replaced by the argument that the zoning was made irrelevant by changes in Kendall Square and poorly thought out in the first place.
Forest City proposal returns, highlighting need to save affordable-housing units
The bid to build a giant office and laboratory building near Central Square for Millennium Pharmaceuticals returned to the City Council on Monday with 168 units of affordable housing proposed to be preserved and 20 to be built, even as another 820 affordable-housing apartments are set to expire in roughly the next seven years.
Forest City refiles petition for Millennium building, promising 188 affordable units
Forest City Enterprises said today it is refiling a petition to build an office and laboratory building at 300 Massachusetts Ave. near Central Square, again for use by the pharmaceutical manufacturer Millennium Pharmaceuticals.
Aveo, Ironwood celebrate milestones for kidney cancer, IBS drugs
Two Cambridge life sciences companies are having a good day: Aveo with a potential treatment for victims of kidney cancer and Ironwood for the right to market its Irritable Bowel Syndrome treatment Constella in the European Union.
Biogen executives, returning to Kendall Square, want zoning rule eased
There’s only one thing standing between Biogen Idec returning to Cambridge, if a report from the Community Development Department is true: a zoning requirement putting a cafeteria on the ground floor of the biotech company’s headquarters and opening it to the public 20 hours a week.
Ironwood adds 93,000 square feet to hold new staff, signs lease into 2018
When Ironwood Pharmaceuticals’ chief executive said the biotech company was staying in Cambridge, he was serious.
Idenix moving to larger space, with neighbors hoping for quiet afterward
Idenix Pharmaceuticals is moving within Kendall Square to a life sciences building with more room for its workers, a company official said, while a neighbor said he was “delighted” the company’s noise would be moving farther from the area’s homes.
